ARTICLE | Product Development
Diadem’s prognostic Alzheimer’s blood test bets on p53 biology
The Italian company plans to launch its test as a screening tool late this year
October 8, 2021 5:24 PM UTC
As blood tests for Alzheimer’s gain momentum as diagnostics and therapeutic response monitoring tools, Italian company Diadem is positioning its unfolded p53 assay as a prognostic screening technology that can predict disease up to six years before diagnosis.
The University of Brescia spinout, which presented data Tuesday at the 22nd International Conference on Alzheimer’s Drug Discovery, hopes to receive European in vitro diagnostic (IVD) certification by year-end, and is in discussions with large CLIA labs in the U.S. to bring the test stateside...